IRIX Stock Analysis: Buy, Sell, or Hold?
IRIX - Iridex Corp
$0.93
0.05 (5.69%)
â˛
5d:
+4.53%
30d:
+0.49%
90d:
-8.36%
WAIT
LOW Confidence
Analysis Updated: Aug 18, 2026 12:00 AM ET
Earnings: Aug 18, 2026
0d
Get Alerted When IRIX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: IRIX is fairly priced but lacks strong directional signals. At -3.7% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: IRIX is fairly priced but lacks strong directional signals. At -3.7% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: IRIX is currently trading at $0.93, which is considered fair relative to its 30-day fair value range of $0.82 to $0.97. From a valuation perspective, the stock is trading at a discount (Forward PE: 46.5) compared to its historical average (52.0). Remarkably, the market is currently pricing in an annual earnings decline of 3.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, IRIX is in a downtrend. Immediate support is located at $0.81, while resistance sits at $0.98. The stock is showing strong short-term momentum, up 5.7% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $2.75 (+195.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IRIX is in a downtrend. Immediate support is located at $0.81, while resistance sits at $0.98. The stock is showing strong short-term momentum, up 5.7% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $2.75 (+195.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.82 -
$0.97
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.7%)
- BULLISH: Trading 195.7% below Wall St target ($2.75)
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.82 -
$0.97
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.81
Resistance Level
$0.98
Current Trend
Downtrend
Technical data as of
Aug 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
46.51
Wall Street Target
$2.75
(+195.7%)
Revenue Growth (YoY)
-0.8%
Profit Margin
-6.2%
Valuation Discount vs History
-3.7% cheaper
PE vs Historical
46.5 vs 52.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.7%
(market-implied from PE analysis)
1-Year Target
$0.90
(-4%)
2-Year Target
$0.86
(-7%)
3-Year Target
$0.83
(-11%)
3-Yr Target (if PE normalizes)
(PE: 47â52)
$0.93
(0%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 46.5 to 52.0
Stabilization Target:
$1.04
(+11.8%)
PE Expansion Potential:
+11.8%
Share & Embed Analysis
Last updated: August 19, 2026 1:13 AM ET
Data refreshes hourly during market hours. Next update: 2:13 AM
Data refreshes hourly during market hours. Next update: 2:13 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRIX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 41 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 53 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 55 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 35 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$119 | 32 SELL |
